Kane Biotech is a biotechnology company developing products to prevent and disperse biofilms, which develop when bacteria and other microorganisms form a protective matrix to shield against attack. Bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures, and host immune responses when in a biofilm, and this resiliency contributes to human health problems like recurrent urinary tract infections, medical device-associated infections, and tooth decay.
The company uses a patent-protected technology that is based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. Kane Biotech has evidence indicating that this technology will potentially improve the ability to prevent and/or destroy biofilms in various medical and industrial applications.
Estimated to be responsible for 80% of all human infections, biofilms cost industry, cities, and hospitals more than $500 billion every year. Based on its ability to screen for factors affecting biofilm formation, Kane Biotech has a growing pipeline of products and has developed candidate products based on the demand for safe and effective anti-biofilm compounds.
Formed in 2001, Kane Biotech aims to become a world leader in creating innovative technology for breaking down and dispersing biofilms and for developing unique products to positively impact human health. The company's mission is discovering and commercializing compelling technology to prevent and cure infections in healthcare and animal agriculture, as well as offering solutions to biofilm-related problems in industrial applications.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net